Pfizer executives said on Tuesday they are confident of strong demand for the company's COVID-19 antiviral treatment amid easing pandemic rules, AFP reported.
The US pharmaceutical giant, reporting surging first-quarter profits based on a big jump in revenues from its COVID-19 vaccine, said its Paxlovid treatment for the virus would be a valuable means for governments to limit the severity of outbreaks as they ease social distancing and masking rules.
Read more